These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8357894)

  • 1. Cost-effectiveness of mammographic screening in Australia.
    Carter R; Glasziou P; van Oortmarssen G; de Koning H; Stevenson C; Salkeld G; Boer R
    Aust J Public Health; 1993 Mar; 17(1):42-50. PubMed ID: 8357894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of mammographic screening strategies.
    Lindfors KK; Rosenquist CJ
    JAMA; 1995 Sep; 274(11):881-4. PubMed ID: 7674501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost utility analysis of mammography screening in Australia.
    Hall J; Gerard K; Salkeld G; Richardson J
    Soc Sci Med; 1992 May; 34(9):993-1004. PubMed ID: 1631612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of breast cancer screening in women on dialysis.
    Wong G; Howard K; Chapman JR; Craig JC
    Am J Kidney Dis; 2008 Nov; 52(5):916-29. PubMed ID: 18789566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors.
    de Koning HJ; van Ineveld BM; van Oortmarssen GJ; de Haes JC; Collette HJ; Hendriks JH; van der Maas PJ
    Int J Cancer; 1991 Oct; 49(4):531-7. PubMed ID: 1917154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age.
    Salzmann P; Kerlikowske K; Phillips K
    Ann Intern Med; 1997 Dec; 127(11):955-65. PubMed ID: 9412300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
    Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
    J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer screening; cost-effective in practice?
    De Koning HJ
    Eur J Radiol; 2000 Jan; 33(1):32-7. PubMed ID: 10674787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland.
    de Gelder R; Bulliard JL; de Wolf C; Fracheboud J; Draisma G; Schopper D; de Koning HJ
    Eur J Cancer; 2009 Jan; 45(1):127-38. PubMed ID: 19038540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammographic screening: measurement of the cost in a population based programme in Victoria, Australia.
    Hurley SF; Livingston PM; Thane N; Quang L
    J Epidemiol Community Health; 1994 Aug; 48(4):391-9. PubMed ID: 7964340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors.
    Neeser K; Szucs T; Bulliard JL; Bachmann G; Schramm W
    Value Health; 2007; 10(1):42-53. PubMed ID: 17261115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening mammography in women aged 40-49 years: analysis of cost-effectiveness.
    Rosenquist CJ; Lindfors KK
    Radiology; 1994 Jun; 191(3):647-50. PubMed ID: 8184041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of breast cancer screening.
    van der Maas PJ; de Koning HJ; van Ineveld BM; van Oortmarssen GJ; Habbema JD; Lubbe KT; Geerts AT; Collette HJ; Verbeek AL; Hendriks JH
    Int J Cancer; 1989 Jun; 43(6):1055-60. PubMed ID: 2499553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models.
    Obdeijn IM; Heijnsdijk EA; Hunink MG; Tilanus-Linthorst MM; de Koning HJ
    Eur J Cancer; 2016 Aug; 63():135-42. PubMed ID: 27318001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the Norwegian breast cancer screening program.
    van Luijt PA; Heijnsdijk EA; de Koning HJ
    Int J Cancer; 2017 Feb; 140(4):833-840. PubMed ID: 27861849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand.
    Szeto KL; Devlin NJ
    Health Policy; 1996 Nov; 38(2):101-15. PubMed ID: 10160378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials.
    de Koning HJ; Boer R; Warmerdam PG; Beemsterboer PM; van der Maas PJ
    J Natl Cancer Inst; 1995 Aug; 87(16):1217-23. PubMed ID: 7563167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
    Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
    Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of breast cancer and the cost-effectiveness of breast cancer screening.
    Elixhauser A
    Int J Technol Assess Health Care; 1991; 7(4):604-15. PubMed ID: 1778705
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.